Scientists have made a groundbreaking discovery in understanding the human brain’s unique genetic features, which could lead to new therapies for conditions such as Parkinson’s disease and schizophrenia. By comparing human and primate brain cells, researchers found that human dopamine neurons express more genes that boost the activity of damage-reducing antioxidants, allowing them to cope…
cancer on The Soothsayer / page 3
The article highlights six antisense oligonucleotide companies leading the way in this emerging field. These companies, including Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, and Wave Life Sciences, are developing innovative treatments for various diseases. The global antisense oligonucleotides market is projected to grow significantly, driven by the ability of these treatments…
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression. Several companies are advancing candidates relying on miRNAs in 2024, with potential applications in disease diagnosis and treatment. Companies such as aceRNA Technologies, ARTHEx Biotech, and Transcode Therapeutics are developing innovative miRNA-based therapeutics for various diseases, including cancer, cardiovascular…
Gene therapy has emerged as a transformative approach in modern medicine, offering a potential cure for a wide array of genetic disorders. By introducing, modifying, or repairing genetic material within a patient’s cells, gene therapy aims to rectify underlying genetic defects, thereby treating or preventing disease. The field has witnessed significant milestones, with several gene…
The biotech industry is witnessing a surge in the development of bispecific antibodies, a type of targeted therapy that can deliver two-in-one treatments to patients with cancer and other diseases. Several companies, including Adaptin Bio, Akeso, AP Biosciences, Candid Therapeutics, Summit Therapeutics, and Zenas BioPharma, are working on various bispecific antibody candidates, some of which…
Researchers from China and Spain have developed a nanoflake-based breath sensor that can detect lung cancer with unprecedented accuracy. The sensor, made from platinum-loaded nanoflakes, can detect isoprene levels in exhaled breath, a biomarker for lung cancer. The device has shown promising results in clinical trials, distinguishing between healthy individuals and lung cancer patients with…
Eight biotech companies are making significant strides in breast cancer treatment, with innovative approaches and therapies showing promise in clinical trials. Arvinas, BioNTech, Carrick Therapeutics, Context Therapeutics, Hummingbird Bioscience, Oncolytics Biotech, Olema Pharmaceuticals, and Relay Therapeutics are among the companies pushing the boundaries of cancer treatment, offering new hope for patients and their families. In…
Researchers in Switzerland have made a significant breakthrough in cancer treatment by developing a hybrid approach that combines ultrahigh-dose-rate (UHDR) electron beams with conventional dose-rate (CDR) photon beams. This innovative technique, known as FLASH radiotherapy, has the potential to spare healthy tissues while effectively targeting malignant tumour cells. The study, published in Radiotherapy and Oncology,…
The biotech industry is witnessing a surge in the development of exosome therapy companies, which are harnessing the potential of these tiny vesicles to treat a range of diseases, including cancer, neurological disorders, and inflammatory diseases. With several companies advancing their candidates through clinical trials, the global exosome therapeutics market is expected to grow significantly…
A team of researchers from the USA and Cameroon has developed a non-invasive device that can detect malaria without requiring a single drop of blood. The device, called Cytophone, uses photoacoustic flow cytometry to rapidly identify malaria-infected red blood cells. Initial testing in 30 Cameroonian adults diagnosed with uncomplicated malaria showed promising results, with 95%…